Xortx announces change of auditor

Calgary, alberta, jan. 17, 2025 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the company has changed its auditor from smythe llp, chartered professional accountants (“former auditor”) to davidson & company llp, chartered professional accountants, (“successor auditor”) effective january 16, 2025.
XRTX Ratings Summary
XRTX Quant Ranking